BBI-001
Small molecule
BBI-001 is one of 6 small molecule programs targeting Hereditary Hemochromatosis. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Hereditary Hemochromatosis
#DrugCompanyPhaseTrials
1Exjade
NovartisPhase 2
PTG-300
Protagonist TherapeuticsPhase 2
Vamifeport
CSL BehringPhase 2
LJPC-401
LLa Jolla Pharmaceutical Company
Phase 2
Protonix
WWyeth-Lederle Vaccines
Preclinical
BBI-001
BBond Biosciences
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BBI-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- BBond Biosciences